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S U M M A R Y
Objectives: The aim of this study was to evaluate the in vitro activities of antimicrobial agents including
fosfomycin tromethamine against Gram-negative isolates recovered from urine samples.
Methods: A total of 2334 strains (1562 Escherichia coli, 509 Klebsiella spp, 85 Proteus spp, 75 Pseudomonas
spp, 45 Enterobacter spp, 37 Acinetobacter baumannii, 8 Citrobacter spp, 7 Morganella morganii, and 6
Serratia spp) were identiﬁed by VITEK 2 during the study period, November 2008 to June 2012.
Antimicrobial susceptibilities of the strains were also evaluated using the Kirby–Bauer disk diffusion
method, in accordance with the Clinical and Laboratory Standards Institute guidelines.
Results: Overall, 2160 (92.5%) of the isolates tested were susceptible to fosfomycin tromethamine.
Higher resistance rates were observed among inpatients compared to outpatients. Resistance rates by
strain were: 2.0% for E. coli, 4.4% for Enterobacter spp, 6.9% for Klebsiella spp, 9.4% for Proteus spp, 48.6% for
A. baumannii, 56.0% for Pseudomonas spp, and 100% for Morganella morganii. All Serratia spp and
Citrobacter spp strains were susceptible. Extended-spectrum beta-lactamase (ESBL)-producing isolates
displayed higher fosfomycin resistance rates than negative strains (19.2% vs. 2.9%). The highest in vitro
activity was detected for amikacin, piperacillin–tazobactam, and imipenem for all strains including
ESBL-producers.
Conclusions: Regardless of ESBL production, the excellent activity of fosfomycin against E. coli,
Enterobacter spp, Serratia spp, and Citrobacter spp, indicates that the drug is a valuable therapeutic option
for urinary tract infections, even those with co-trimoxazole- and ciproﬂoxacin-resistant isolates, but not
in ESBL-producing Klebsiella spp, Pseudomonas spp, A. baumannii, and Proteus spp. Further studies should
be carried out to determine the in vivo drug activity among Enterobacteriaceae other than E. coli.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The emergence and spread of multidrug-resistant (MDR) Gram-
negative bacteria related to urinary tract infections (UTIs) is
increasing worldwide, both in hospitals and in the community. The
therapeutic option is a growing concern due to the production of
extended-spectrum beta-lactamases (ESBLs) exhibiting resistance
not only to cephalosporins but also quinolones and co-trimox-
azole.1–6
Fosfomycin inhibits bacterial cell wall biogenesis by inactivat-
ing the enzyme UDP-N- acetylglucosamine-3-enol-pyruvyltrans-
ferase (MurA). It exhibits excellent tissue penetration and impairs
adherence to the urogenital mucosa, and it is excreted unchanged
in high concentrations in the urine.1,3 With the advantages of* Corresponding author. Tel.: +90 3862134515; fax: +90 3862133398.
E-mail address: drtulin@yahoo.com (T. Demir).
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http://dx.doi.org/10.1016/j.ijid.2013.04.005administration as a single dose per day, a good safety proﬁle, no
effect on the anaerobic gut ﬂora, and availability during pregnancy,
this drug is a good option in the treatment of uncomplicated
UTIs.1,3,4,6–8
Fosfomycin tromethamine (FOF), a stable salt of fosfomycin, has
been found to be effective for the treatment of UTIs related to
Escherichia coli, Citrobacter spp, Enterobacter spp, Klebsiella spp,
Serratia spp, and Enterococcus faecalis.3–5,7–9 Although it has been
commonly prescribed in some countries in Europe and the USA for
the treatment of uncomplicated UTIs for several years,3–5,8
resistance rates have so far remained low.4,10,11 Moreover, the
drug was found to be effective against MDR and metallo-beta-
lactamase (MBL)-producing Enterobacteriaceae strains, with sus-
ceptibility rates over 83%.12,13
In the present study, we aimed to determine the in vitro FOF
susceptibility of Gram-negative strains recovered from urine
samples and to compare its activity with the other antimicrobial
agents commonly used for the treatment of UTIs.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Bacterial species distribution in this study
Bacterial strain Number of strains %
Escherichia coli 1562 66.9%
Klebsiella spp 509 21.8%
K. pneumoniae 260
K. oxytoca 249
Proteus spp 85 3.6%
P. mirabilis 72
P. vulgaris 13
Pseudomonas spp 75 3.2%
P. aeruginosa 71
P. luteola 2
P. putida 1
P. ﬂuorescens 1
Enterobacter spp 45 1.9%
E. cloacae 32
E. aerogenes 9
E. sakazakii 4
Acinetobacter baumannii 37 1.6%
Citrobacter spp 8 0.3%
C. freundii 5
C. koseri 3
Morganella morganii 7 0.3%
Serratia spp 6 0.3%
S. fonticola 4
S. marcescens 1
S. liquefaciens 1
Total 2334 100
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2.1. Study design
Urine samples of 10 248 patients with clinical symptoms of UTI
who were referred to the Clinical Microbiology Laboratory of Ahi
Evran University Research and Training Hospital, Kırs¸ ehir (a 340-
bed teaching hospital located in the central region of Turkey)
during the study period of November 2008 to June 2012, were
evaluated. Signiﬁcant bacteriuria is deﬁned by counts of 105 cfu/
ml in the patient’s mid-stream urine sample. A total of 2334
bacterial strains (1562 E. coli, 509 Klebsiella spp, 85 Proteus spp, 75
Pseudomonas spp, 45 Enterobacter spp, 37 Acinetobacter baumannii,
8 Citrobacter spp, 7 Morganella morganii, and 6 Serratia spp) were
identiﬁed by VITEK 2 Compact (bioMe´rieux, Marcy l’Etoile, France).
2.2. Antimicrobial susceptibility
Testing of susceptibility to ampicillin (AMP, 10 mg), amikacin
(AMK, 30 mg), amoxicillin–clavulanic acid (AMC, 20/10 mg),
aztreonam (ATM, 30 mg), cefepime (FEP, 30 mg), cefotaxime
(CTX, 30 mg), ceftazidime (CAZ, 30 mg), ceftriaxone (CRO, 30 mg),
cefuroxime (CXM, 30 mg), ciproﬂoxacin (CIP, 5 mg), co-trimoxazole
(SXT, 1.25/23.75 mg), fosfomycin tromethamine (FOF, 200 mg),
gentamicin (GEN, 10 mg), imipenem (IPM, 10 mg), and piperacil-
lin–tazobactam (TZP, 100/10 mg) (Oxoid Ltd, Basingstoke, UK) was
determined by Kirby–Bauer disk diffusion test method in
accordance with Clinical and Laboratory Standards Institute (CLSI)
guidelines,14 and also with the VITEK 2 Compact system. E. coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were used as
quality control strains.
ESBL screening of the isolates was performed by disk synergy
test, and results were conﬁrmed by cefotaxime, ceftazidime,
cefotaxime–clavulanic acid (CTC, 30/10 mg), and ceftazidime–
clavulanic acid (CZC, 30/10 mg) disks, in accordance with CLSI
guidelines.14 E. coli ATCC 25922 (ESBL-negative) and Klebsiella
pneumoniae ATCC 700603 (ESBL-positive) were used as quality
control strains for the phenotypic testing of ESBL production.
The minimum inhibitory concentration (MIC) for imipenem
was determined by Etest method (AB Biodisk, Solna, Sweden)
following the manufacturer’s instructions, for strains resistant or
intermediately resistant to imipenem by disk diffusion test.
Additionally, the MBL Etest strip (AB Biodisk, Solna, Sweden)
was used to determine MBL production for the strains resistant or
intermediately resistant to imipenem. Several colonies from a 24-h
culture plate were used to prepare the inoculum with a 0.5
McFarland standard density, and Mueller–Hinton agar plates were
streaked using cotton swabs. The Etest MBL strips were then
applied, and the plates were incubated at 35 8C in air for 16–20 h. A
ratio of the MICs of the imipenem (IP) to imipenem plus
ethylenediaminetetraacetic acid (EDTA) (IPI) of 8, or the presence
of a phantom zone, i.e., an extra inhibition zone between the IP and
IPI regions, or a deformation of the IP or IPI ellipses, was
interpreted as being positive for MBL production.
2.3. Statistical analyses
Data were analyzed using SPSS software 15.0 (SPSS, Inc., Chicago,
IL, USA). Comparisons of categorical variables were done using Chi-
square tests, although Fisher’s exact test was used when data were
sparse. Signiﬁcance was set at p < 0.05 using two-sided comparisons.
3. Results
A total of 2334 bacterial strains recovered from 10 248 urine
samples of 434 (18.6%) inpatients and 1900 (81.4%) outpatientswere included in the study. The most commonly isolated
pathogens were E. coli (66.9%) and Klebsiella spp (21.8%).
Identiﬁcation of the strains to the species level is shown in
Table 1. Of the 2334 bacterial strains, ESBL production was
detected in 651 (27.9%) isolates; the distribution for E. coli,
Klebsiella spp, Enterobacter spp, Proteus spp, M. morganii, and
Citrobacter spp were 408 (26.1%), 124 (24.4%), 16 (35.6%), 3 (3.5%), 2
(28.6%), and 2 (25%), respectively. Among nonfermenting strains,
80% (n = 60) of Pseudomonas spp and 97.3% (n = 36) of A. baumannii
strains were ESBL-producers.
Antimicrobial resistance rates of the isolates belonging to the
Enterobacteriaceae family (n = 2222) tested in this study were as
follows: 71.6% to ampicillin, 38.7% to co-trimoxazole, 28.2% to
cefuroxime, 25.4% to ciproﬂoxacin, 18.7% to gentamicin, 11.8% to
amoxicillin–clavulanic acid, 5.5% to piperacillin–tazobactam, 3.7%
to FOF, 2.3% to amikacin, and 0.04% to imipenem. Twenty-ﬁve
percent of the strains were resistant to any of the third-generation
cephalosporin group. Antimicrobial resistance rates in relation to
species are shown in Table 2. Imipenem was the most active agent
against all strains except Acinetobacter spp. Overall, 33 of the
isolates tested (1 E. coli, 1 K. pneumoniae, 4 P. aeruginosa, 26 A.
baumannii, and 1 Pseudomonas luteola) showed resistance or
intermediate resistance to imipenem, and all strains but one A.
baumannii were found to be MBL-producers by MBL Etest, with
MIC ratios of IP/IPI ranging from 1/16 to 1/256.
Of the 2334 strains, 2160 (92.5%) were susceptible to
fosfomycin, 143 (6.1%) showed resistance, and 31 (1.3%) displayed
intermediate resistance. E. coli strains displayed higher antimicro-
bial activity for fosfomycin compared to other strains (p < 0.05).
The resistance rate was higher among inpatient strains than among
outpatient strains: 17.5% vs. 5.2% (odds ratio (OR) 3.90, 95%
conﬁdence interval (CI) 2.83–5.38; p = 0.001). In addition, higher
resistance rates were detected among inpatient compared to
community strains: 7.9% vs. 4.3%, respectively, among Enterobac-
teriaceae.
In this study, the most common pathogens causing UTI were E.
coli (66.9%) and Klebsiella spp (21.8%). Klebsiella spp strains
displayed higher rates of fosfomycin resistance compared to E.
coli strains: 10.8% vs. 2.2% (OR 5.44, 95% CI 3.51–8.46; p = 0.001).
Table 2
Distribution of resistance rates of all isolates by strain type (n = 2334)
Antimicrobial Escherichia coliKlebsiella sppEnterobacter sppProteus sppMorganella sppSerratia sppCitrobacter sppPseudomonas sppAcinetobacter baumannii
Ampicillin 69.5 79.6 84.4 55.3 85.7 50.0 87.5 98.7 100.0
Amoxicillin–clavulanic acid 10.3 13.9 42.2 4.7 71.4 16.7 12.5 90.7 70.3
Amikacin 2.1 2.9 4.4 - - - 12.5 12.0 73.0
Cefuroxime 28.9 28.3 44.4 7.1 57.1 - 25.0 92.0 97.3
Third-generation cephalosporin26.1 24.4 35.6 3.5 28.6 - 25.0 80.0 97.3
Ciproﬂoxacin 29.5 18.7 6.7 3.5 28.6 - - 24.0 81.1
Fosfomycin 2.0 6.9 4.4 9.4 100 - - 56.0 48.6
Gentamicin 19.6 17.7 8.9 11.8 57.1 - 12.5 20.0 75.7
Imipenema 0.1 0.2 - - - - - 6.7 70.2
Co-trimoxazole 41.7 30.8 13.3 47.1 57.1 - 26.0 92.0 64.9
Piperacillin–tazobactam 4.7 9.4 2.2 1.2 - - - 12.0 81.1
a Intermediately resistant test results were evaluated as resistant.
Table 4
Distribution of fosfomycin susceptibilities of the isolates by strain type and
T. Demir, T. Buyukguclu / International Journal of Infectious Diseases 17 (2013) e966–e970e968For all antimicrobials tested, ESBL-producer Enterobacteriaceae
strains showed lower susceptibility rates compared to non-
producers (p < 0.05). Resistance rates for ciproﬂoxacin, co-
trimoxazole, and gentamicin were over 45% among ESBL-
producers (Table 3). Of the ESBL-positive Enterobacteriaceae strains
(n = 555), 49 (8.8%) were resistant and 13 (2.3%) showed
intermediate resistance to fosfomycin, displaying an overall
susceptibility rate of 88.8%. Moreover, higher resistance to
fosfomycin was observed for ESBL-positive strains compared to
non-producer isolates (11.2% vs. 2.8%; p = 0.001). Fosfomycin
resistance was not detected among Serratia spp or Citrobacter spp,
but all Morganella spp strains were resistant to this drug.
Regardless of ESBL production, the highest in vitro activity was
detected against E. coli strains. Among Klebsiella spp strains, ESBL-
producer strains showed higher resistance rates compared to non-
producer isolates: 17.7% vs. 3.4%. The distribution of fosfomycin
susceptibility rates of the isolates by strain type and ESBL
production is shown in Table 4.
Among strains resistant to antimicrobials tested in this study,
fosfomycin showed higher in vitro activity (over 80%) against
Enterobacteriaceae strains compared to nonfermenting strains (A.
baumannii and Pseudomonas spp) (below 45%).
Overall, the resistance rates of the isolates tested to co-
trimoxazole and ciproﬂoxacin were 89.2% and 89.7%, respectively.
Fosfomycin was found to be effective against strains resistant to
co-trimoxazole and ciproﬂoxacin, displaying susceptibility rates of
94.6% and 93.3% for Enterobacteriaceae and 39.4% and 40.8% for
nonfermenting Gram-negative bacilli.
Among E. coli strains, the most active agents regardless of ESBL
production were imipenem (99.9%) and fosfomycin (97.8%),
followed by amikacin (96.9%) and piperacillin–tazobactamTable 3
Distribution of antimicrobial resistance rates of Enterobacteriaceae (n = 2222) by
extended-spectrum beta-lactamase (ESBL) production
Antimicrobial agents ESBL (%)
Negative (n = 1667) Positive (n = 555)
Ampicillin 1052 (63.1) 555 (100)
Amoxicillin–clavulanic acid 113 (6.8) 187 (33.7)
Gentamicin 165 (9.9) 267 (48.1)
Amikacin 7 (0.4) 63 (11.4)
Cefuroxime 82 (4.9) 555 (100)
Piperacillin–tazobactam 26 (1.6) 114 (20.5)
Ciproﬂoxacin 247 (14.8) 331 (59.6)
Co-trimoxazole 547 (32.8) 319 (57.5)
Fosfomycin 46 (2.8) 62 (11.2)
Imipenem - 2 (0.4)a
Intermediately resistant isolates were evaluated as resistant in the statistical
analysis.
a Fisher’s exact test.(94.6%). Comparison of the in vitro efﬁcacy of the antimicrobials
by strain type and ESBL production is shown in Figure 1.
4. Discussion
Fosfomycin is a cell wall active antimicrobial agent found to be
effective against E. coli, Citrobacter spp, Enterobacter spp, Klebsiella
spp, Serratia spp, and E. faecalis related UTIs.7,13,15,16 Although it has
been used for several years, resistance has remained low, at 0.3–
2.8% in E. coli4,11,17–19 and 7.2–28.6% in Klebsiella spp.17,19 The CLSI
recommends fosfomycin therapy only for the treatment of
uncomplicated UTIs related to E. coli.14 The explanation for this
limitation is the reported discrepancies between disk diffusion and
agar dilution tests observed for Klebsiella spp strains19,20 in contrast
to the good correlation in E. coli isolates.20,21 Further studies are
required to assess the activity against Klebsiella spp strains.
The present study compared the in vitro efﬁcacy of FOF with
that of other antimicrobials, against 2334 Gram-negative bacterial
isolates representing nine species. The most common pathogens
recovered from urine were E. coli and Klebsiella spp. Overall, 6.1% of
the isolates tested were resistant and 1.3% showed intermediate
resistance to fosfomycin. Higher rates of resistance were detected
among Klebsiella spp compared to E. coli strains (10.8% vs. 2.2%; p <
0.05), supporting the data published previously.17,18,22–24
ESBL production among Enterobacteriaceae is a growing concern
worldwide. In this study, nearly a quarter of the strains wereextended-spectrum beta-lactamase (ESBL) production
Bacterial isolate Fosfomycin susceptibility rate (%)
Total ESBL
Negative Positive
Escherichia coli (n = 1562) 97.8 99.1 94.1
Klebsiella spp (n = 509) 89.2 94.2 73.3
K. pneumoniae 84.6 91.5 66.1
K. oxytoca 94 96.9 83.0
Enterobacter spp (n = 45) 93.3 93.1 93.7
E. cloacae 90.6 88.2 93.3
E. sakazakii 100 100 100
E. aerogenes 100 100 -
Proteus spp (n = 85) 89.4 91.4 50
P. mirabilis 94.4 95.7 50
P. vulgaris 61.5 66.6 -
Morganella morganii (n = 7) - - -
Serratia spp (n = 6) 100 100 -
Citrobacter spp (n = 8) 100 100 100
Acinetobacter baumannii (n = 37) 35.1 100 33.3
Pseudomonas spp (n = 75) 44 80 35
Figure 1. Antimicrobial resistance rates of the strains by extended-spectrum beta-lactamase production.
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in the FOF resistance rate was not detected among E. coli strains
(0.9% vs. 5.9%), but a major distinction was observed for Klebsiella
spp (5.7% vs. 26.6%, the latter being the ESBL-producer). In previous
studies on ESBL-producers, FOF resistance rates of 0–9.1% for E.
coli1–3,5,19,21,23,24 and 18.7–42.4% for Klebsiella spp21,23 were
reported. The low level of resistance among E. coli strains could
be explained with the drug’s limited use for the treatment of
uncomplicated UTIs,4,10,11,17–19,22 suggesting that fosfomycin is the
drug of choice for the treatment of UTIs, especially those caused by
E. coli.
Co-trimoxazole is the recommended drug for the treatment of
UTIs in settings where the resistance is <10–20%,18 and quinolones
are the drugs of choice if the co-trimoxazole resistance is higher
than 20%.25 Several studies have shown ciproﬂoxacin and co-
trimoxazole to be highly active against E. coli, with susceptibility
rates over 81–99%17,18,20,21,26,27 and 64–82%,17,18,21,26,27 respec-
tively, in contrast to dramatically decreasing susceptibility rates
among ESBL-producers for ciproﬂoxacin and co-trimoxazole, 19–
36% and 33–43%, respectively.2,5 In this study, lower susceptibility
rates for ciproﬂoxacin and co-trimoxazole were obtained: 70.5%
and 38.3% in E. coli, and 81.3% and 69.2% in Klebsiella spp,
respectively. The high levels of resistance to co-trimoxazole and
ciproﬂoxacin reported in this study and previously18 may indicate
the misuse of these drugs for both inpatients and outpatients in our
country, and it is clear that ciproﬂoxacin and co-trimoxazole
therapy should be evaluated with caution in the treatment of UTI.
In agreement with some reports,22 fosfomycin appears to be an
important treatment option for UTIs associated with E. coli and
Klebsiella spp, even quinolone- and co-trimoxazole-resistant
strains, with susceptibility rates of 93.3% and 94.6%, respectively.
Several studies have shown that community-acquired ESBL-
producing E. coli urinary isolates have high resistance rates to most
of the currently used oral antimicrobial agents, with resistance
rates of 84% for ciproﬂoxacin, 75% for co-trimoxazole, 15% for
nitrofurantoin, and 0% for fosfomycin,28 suggesting the use of
fosfomycin and nitrofurantoin for the ﬁrst-line empirical oral
treatment of community-acquired uncomplicated UTIs. A single
dose of FOF was found to be as effective as ciproﬂoxacin in the
treatment of uncomplicated UTIs.29 In a multicenter study, FOF,
ciproﬂoxacin, and co-trimoxazole susceptibility rates were 99%,
98.3%, and 87.8%, respectively, among E. coli strains recovered from
female patients with symptoms of uncomplicated cystitis; it was
stated that co-trimoxazole and quinolones are not recommended
as ﬁrst-line drugs for the empiric treatment of uncomplicated
cystitis because of the increasing resistance rates.30
Four drugs, FOF, amikacin, piperacillin–tazobactam, and
imipenem, were found to have maintained high activity against
ESBL-producers in this study. For FOF the explanation lies in the
decreased ﬁtness of E. coli after acquiring a mutation that confers
resistance to this drug,31 which allows the strains without the
mutation to grow faster and displace the resistant ones. The
explanation for amikacin, piperacillin–tazobactam, and imipenemis probably the fact that these drugs are used only in a hospital
setting and generally not as the ﬁrst-line therapy option. In
contrast to many reports indicating low resistance rates to
gentamicin (4–8%18,24 for E. coli and 13–16%2,5 for ESBL-positive
E. coli strains), higher rates were detected for E. coli and ESBL-
positive E. coli strains in this study (19.6% and 49%, respectively). It
is clear that gentamicin should be used with caution in UTIs related
to ESBL-producer E. coli strains.
Susceptibilities to fosfomycin of Enterobacteriaceae other
than E. coli and Klebsiella spp were not extensively studied. In the
limited number of studies available, susceptibility rates of
Proteus mirabilis, Proteus vulgaris, M. morganii, and Enterobacter
spp were 73.8–87.5%, 50%, 0%, and 82.9%, respectively.10,17
Additionally, more than 90% of the E. coli and Citrobacter spp,
more than 70% of Klebsiella spp, Enterobacter spp, and P. mirabilis
strains, 31.8% of P. aeruginosa, and 11.1% of Acinetobacter spp
strains were reported to be susceptible to fosfomycin.32 Similar
to previous reports,17 all Morganella spp were resistant to FOF,
but resistance was not detected among Serratia spp and
Citrobacter spp. However, the results should be evaluated with
caution because of the limited numbers of strains. Resistance
rates were higher for Pseudomonas spp and A. baumannii, at 56%
and 48.6%, respectively. High activity was detected for Enter-
obacter spp, with a susceptibility rate of 4.4%, similar to the rate
in a previous report.17 In contrast to reported FOF resistance
rates of up to 40% for Proteus spp,11,17 a lower rate, 9.4%, was
detected, indicating that the drug could be an alternative
therapeutic option for UTIs related with these strains. Good in
vitro activity against E. coli and Klebsiella spp was detected in
several studies. However it is clear that further studies should be
performed to determine and evaluate the drug efﬁcacy in vivo for
strains other than E. coli and Klebsiella spp.
In this study we could not classify complicated or uncompli-
cated UTIs due to the lack of information in the database
concerning patients’ previous treatment with antibiotics, previous
hospitalization, and risk factors for UTIs. This is a clear limitation of
this study. However, to our knowledge, this is the ﬁrst study
conducted on a large scale to evaluate antimicrobial susceptibili-
ties of Gram-negative bacterial strains other than E. coli and
Klebsiella spp recovered from UTIs.
Several analyses of fosfomycin activity against E. coli strains
over the last decade have shown excellent susceptibility rates of
over 93% regardless of ESBL production,1–3,5,12,19,21,23,24,27,33
although an increase in resistance has been reported from Spain
and Japan.5,33 It is clear that in the following years FOF use will gain
importance due to the strains producing ESBL and increasing
resistance to co-trimoxazole and quinolones.
In conclusion, it is clear that FOF could be an alternative
treatment option for UTIs related to E. coli and Klebsiella spp, but
not for ESBL-producing Klebsiella spp. Although in vitro data seem
to encourage the prescription of FOF, further clinical studies
evaluating the clinical efﬁcacy and safety proﬁle of this drug
should be conducted.
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